Clinical trial
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
NCT00218322 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00218322 |
|---|---|
| Title | Effectiveness of ATMX in Treating Adolescents With ADHD and SUD |
| Official title | Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders |
| Intervention type | Drug |
| Interventions | Atomoxetine hydrochloride, Placebo |
| Enrollment | 108 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: